The Responsibility That Comes With Hope

Mike Zuendel is a close friend of mine. He has lived through things that would break most people. When his wife died young, he was left to raise their children alone — eleven weeks, three years, and seven years old. He persevered through that grief while building a successful business career and pouring himself into his community. In time, he met and married Brooks, the second love of his life, and began a new chapter grounded in gratitude.

Then, at sixty-five, he was diagnosed with mild cognitive impairment, often an early stage of Alzheimer’s disease. When we speak now, there is a quiet question beneath the conversation. Is anything coming? And if so, when? I never have a simple answer.

Nearly seven million Americans are living with Alzheimer’s, and another 12 million are living with mild cognitive impairment, the same diagnosis Mike received. Behind each statistic is a family recalibrating daily life around a condition that often stays in the shadows until it is too late to ignore. For these 19 million Americans and their loved ones, the urgency is real. Every day matters.

In that environment, it is natural to argue that anything promising should move as quickly as possible toward patients. That instinct comes from compassion. But urgency and effectiveness are not always aligned. The difference between something that helps a few people quickly and something that helps millions reliably is not ambition. It is foundation and follow-through.

Alzheimer’s research has learned this the hard way. In 2021, the FDA’s accelerated approval of aducanumab over the objections of its own advisory panel ignited one of the most consequential debates in recent medical history. The therapy had shown early biological signals. Whether those signals translated into meaningful clinical benefit was, and remains, contested. Medicare ultimately restricted coverage to clinical trial participants. Neurologists were divided. Public trust, already fragile in a field that had disappointed families for decades, weakened further.

The episode did not invalidate the scientific effort. But it illustrated what happens when a field moves before its infrastructure is ready: standards of care go unsettled, payers hesitate, and the physicians who might otherwise champion a new approach hold back.

That pattern has consequences beyond any single therapy. When confidence erodes, the entire field slows. Patients in trials find it harder to enrol. Reimbursement pathways become more contested. Clinicians become more conservative. What begins as an attempt to accelerate access can end up delaying it.

Any field with a history this complex depends not only on scientific discovery but on disciplined stewardship. Resources, whether from public institutions, philanthropy, or private enterprise, are not a trophy. They are a mandate for rigour and restraint. They provide the time and space to resist shortcuts and to prioritise the less visible work: strengthening diagnostics, refining delivery models, building longitudinal data, and ensuring that what works in a controlled study can endure in ordinary practice.

Durability rarely makes headlines. It looks like unglamorous work: protocol amendments, endpoint validation, payer engagement, and physician education. It requires careful study, disciplined execution, and a willingness to answer difficult questions about long-term outcomes, implementation, and consistency. This work can feel agonisingly slow to families watching the decline in real time. But the tradeoff runs in both directions. Expanding too quickly without a stable foundation can set a field back years. When that happens, it is patients who pay the price.

Responsibility in medicine is not only about intention. It is about stewardship.

That stewardship demands a clear north star. Patients must come before headlines, before quarterly targets, before the pressure to be first. When there is tension between speed and certainty, between announcing progress and proving it, the question cannot simply be whether something can be brought forward. It must be whether doing so serves patients not just in the moment, but over the long arc of their lives. Sometimes what is best for patients is not what is quickest. It is what is most durable.

Hope has sustained Alzheimer’s research through decades of frustration. It motivates scientists, clinicians, caregivers, and patients alike. But hope without structure has disappointed people before. The responsibility that comes with hope is not simply to offer it. It is to build something worthy of it.

When Mike asks whether anything is coming, he is not asking for a fragile promise or a headline. He is asking whether this time will be different — whether the science will translate into something dependable, and whether the system around it will hold.

If progress comes, it will not be because we moved the fastest. It will be because we built something durable enough to earn the trust it requires.